By IANS,
Hyderabad : GVK Biosciences (GVK BIO), leading research and development organisation, Monday said it has been selected as a preferred provider to a consortium of 14 global product development partners (PDPs) for clinical services in Asia.
The product development partners, funded in part by the Bill and Melinda Gates Foundation, are not-for-profit entities focused on developing new interventions for diseases such as tuberculosis, malaria, kala-azar, HIV/AIDS, childhood pneumonia and diarrheal diseases, a statement said.
Collectively the 14 PDPs anticipate funding 85 clinical trials in the developing world over the next two years and India features as a key developing country.
GVK BIO is the only partner headquartered in India.
The firm is currently working with some of the PDPs and collaborating with investigators and public institutions in India and Bangladesh to help develop preventive and therapeutic modalities that can eventually be introduced into public health programmes, the statement added.
It will collaborate with the consortium as a niche service provider for clinical monitoring, logistics support and safety monitoring apart from overall project management.
“GVK Biosciences is extremely pleased to support the development of health solutions for neglected infectious diseases in India,” Manni Kantipudi, chief executive officer, said.
GVK BIO’s diverse portfolio of more than 150 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic institutions.